Evidence map›Paper›PMID 39476194›Full record

ArticleCancer communications (London, England)2025

Wnt/GSK-3β mediates posttranslational modifications of FLYWCH1 to regulate intestinal epithelial function and tumorigenesis in the colon.

Sheema Almozyan, Roya Babaei-Jadidi, Abrar Aljohani, Sepideh Youssefi, William Dalleywater, Prerna Kadam, Bradley Spencer-Dene, Emad Rakha, Mohammad Ilyas, Abdolrahman Shams Nateri

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sheema AlmozyanCancer Genetics & Stem Cell Group, BioDiscovery Institute, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
Roya Babaei-JadidiCancer Genetics & Stem Cell Group, BioDiscovery Institute, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
Abrar AljohaniUniversity of Nottingham and Nottingham University City Hospital, School of Medicine, Nottingham, Nottinghamshire, UK.
Sepideh YoussefiCancer Genetics & Stem Cell Group, BioDiscovery Institute, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
William DalleywaterHistopathology, Queens Medical Centre, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
Prerna KadamCancer Genetics & Stem Cell Group, BioDiscovery Institute, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
Bradley Spencer-DeneExperimental Histopathology, The Francis Crick Institute, London, UK.
Emad RakhaUniversity of Nottingham and Nottingham University City Hospital, School of Medicine, Nottingham, Nottinghamshire, UK.
Mohammad IlyasHistopathology, Queens Medical Centre, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.
Abdolrahman Shams NateriCancer Genetics & Stem Cell Group, BioDiscovery Institute, School of Medicine, University of Nottingham, Nottingham, Nottinghamshire, UK.ORCID https://orcid.org/0000-0002-6422-6813

Funding

Medical Research Council G0700763
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39476194
PMCPMC11758259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.